Aptevo Therapeutics reports Q2 2026 results via press release

Aptevo Therapeutics Inc. reported that it released its financial results for the period ended June 30, 2026 through a press release dated August 14, 2026.

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. reported that it released its financial results for the period ended June 30, 2026 through a press release dated August 14, 2026. The company furnished this press release as Exhibit 99.1 to a current report on Form 8-K under the results of operations and financial condition disclosure item. The company specifies that this information is being furnished, not filed, which limits its treatment under certain liability provisions and incorporation-by-reference rules in other SEC reports.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Emerging growth company, furnished and shall not be deemed “filed”, incorporated by reference, Inline XBRL

4 terms

Emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

furnished and shall not be deemed “filed” regulatory

"The information in this report ... is being furnished and shall not be deemed “filed”"

incorporated by reference regulatory

"shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

Earnings Snapshot

Period ended June 30, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aptevo Therapeutics (APVO) disclose in its latest Form 8-K?

Aptevo Therapeutics disclosed that it issued a press release announcing its financial results for the period ended June 30, 2026, furnished as Exhibit 99.1 to a Form 8-K.

Which period do the disclosed Aptevo Therapeutics (APVO) results cover?

The reported financial results for Aptevo Therapeutics cover the period ended June 30, 2026. These results are summarized in a press release furnished as Exhibit 99.1 to the Form 8-K.

How did Aptevo Therapeutics (APVO) provide its June 30, 2026 results to investors?

Aptevo Therapeutics provided its June 30, 2026 results through a press release dated August 14, 2026, which is attached as Exhibit 99.1 and referenced in a Form 8-K.

Are Aptevo Therapeutics’ (APVO) June 30, 2026 results considered filed with the SEC?

No. The company states the information, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of certain Securities Act and Exchange Act liability provisions.

Will the Aptevo Therapeutics (APVO) press release be automatically incorporated into other SEC filings?

No. Aptevo notes the information in the Form 8-K and Exhibit 99.1 will not be incorporated by reference into other SEC filings unless specifically referenced there.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 08:10 AM EDT Learn about SEC filing dates

false000167158400016715842026-08-142026-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2026

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37746	81-1567056
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2401 4th Avenue Suite 1050
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		APVO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2026, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (the “SEC”) made by the Company, whether made before, on or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated August 14, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			APTEVO THERAPEUTICS INC.
Date:	August 14, 2026	By:	/s/ Daphne Taylor
			Daphne Taylor Senior Vice President and Chief Financial Officer

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 40.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.4 KB